Nkarta Inc. (NKTX) is scheduled to report updated clinical data from its ongoing clinical trial of NKX019, its CD19-directed CAR NK cell therapy candidate, today, December 5.
The company is developing allogeneic engineered natural killer (NK) cell therapies to treat cancer.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com